Phillips 66 (PSX)
Billionaire investor Warren Buffett’s Berkshire Hathaway Inc. disclosed in a regulatory filing with the Securities and Exchange Commission (SEC) that it has accumulated 57,975,456 shares of PSX, representing more than a 10% stake in the company. The SEC filing shows the investment firm had been aggressively buying PSX shares since Wednesday of this past week
PSX recently reported second quarter 2015 adjusted earnings of $1.0 billion or $1.83 per share. The company generated $1.4 billion of cash from operations during the period
PSX is a diversified energy manufacturing and logistics company. With a portfolio of Midstream, Chemicals, Refining, and Marketing and Specialties businesses, PSX processes, transports, stores and markets fuels and products globally.
More about Phillips 66 (PSX) at www.phillips66.com
Crown Equity Holdings Inc. (CRWE)
The company is currently developing its CRWE WORLD ( www.crweworld.com ), a community targeted platform which goal is to be a one-stop shop for the various needs of online consumers in a range of marketing specialties like Real Estate, Coupons & Deals, Business Directory and more
CRWE WORLD’s business model is based on selling advertising to businesses targeting their marketing message locally, nationally, internationally and also to target potential clients for an specific location, such as within a certain zip code.
The company’s CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE WORLD Network. It will allow people to submit their listings for exposure to visitors searching for homes.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
uniQure N.V. (QURE)
In a new SEC filing (SC 13G), billionaire Steve Cohen’s Point72 Asset Management, L.P. has disclosed a 5% (1,138,490 shares) stake in QURE
QURE posted second quarter 2015 revenue of EURO1.62 million and a net loss of (EURO18.9) million or (EURO0.87) per share in the period. As of June 30, 2015, the Company held cash and cash equivalents of EURO181.9 million, compared with EURO53.2 million as of December 31, 2014.
QURE is delivering on the promise of gene therapy – single treatments with potentially curative results. The Company is leveraging its modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases.
More about uniQure N.V. (QURE) at www.uniQure.com
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer